1. Home
  2. |Insights
  3. |Finally—A Regulatory Pathway for Biosimilars in the United States

Finally—A Regulatory Pathway for Biosimilars in the United States

Client Alert | 1 min read | 03.26.10

Lost in much of the political fanfare surrounding healthcare reform is that, for the first time, a regulatory pathway for the approval of biosimilar medicines was created when President Obama signed healthcare reform legislation into law. While the European Union has had a regulatory pathway for biosimilars since 2006, the United States, which is by far the world's largest potential market for biosimilars, has not--until now.

The Senate Healthcare Reform Bill that was signed by the President this week will be unchanged by any pending House of Representative amendments. The biosimilar regulatory pathway is now law.The biosimilar regulatory pathway is based on the innovator's or "reference product's" prior FDA approval and determination of safety, purity and potency. Biosimilar applications will be reviewed by the same FDA division as the reference product. To be approved, the application must satisfy two standards:

  • Biosimilar-requires analytics demonstrating that product is "highly similar", preclinical, clinical (including immunogenicity, pharmacokinetics and pharmacodynamics) studies, any of which may be waived by the FDA; and
  • Interchangeability--meeting above biosimilar requirement and (a)"expected to produce same clinical result …in any given patient"; and (b) risk of "safety or diminished efficacy of alternating or switching between use of the [biosimilar] and reference product is not greater than the risk of using the reference product" alone.

Other key features of the new law are

  • No biosimilar applicant can file sooner than 4 years after the reference product is first licensed (4.5 if pediatric request);
  • 12 years of exclusivity for reference products from "first licensure";
  • 1 year of exclusivity after first commercial marketing for first biosimilar applicant;
  • Confidential document exchange and good faith negotiation between applicant and reference product patent owners before patent litigation;
  • 180 day "Notice of Commercial Marketing" by biosimilar applicant to reference product owner prior to marketing;
  • But unlike small molecule generics, there will be no "Orange Book" Listing

Contacts

Insights

Client Alert | 3 min read | 06.12.26

DOJ Guidance Backs Away From Disparate Impact Liability

On June 9, 2026, the U.S. Department of Justice (DOJ) issued a formal opinion concluding that the Equal Opportunity Employment Commission’s (EEOC) existing interpretations of Title VII of the Civil Rights Act of 1964 (Title VII) disparate-impact liability, including the Uniform Guidelines on Employee Selection Procedures (UGESP), are unconstitutional. According to the opinion, EEOC’s prior interpretations contemplate liability based on disproportionately adverse effects alone, without regard to an employer’s likely intent, rather than treating disparate impact as an evidentiary mechanism to “smoke out” intentional discrimination. DOJ found that this approach functions as a “qualified racial-proportionality mandate” that places “a racial thumb on the scales, often requiring employers to evaluate the racial outcomes of their policies, and to make decisions based on (because of) those racial outcomes.” The opinion fulfills one mandate of Executive Order 14281, which rejected disparate-impact liability insofar as it “creates a near insurmountable presumption that unlawful discrimination exists wherever there are any differences in outcomes among different [demographic groups].”...

View All Insights